2015 Q3 Form 10-Q Financial Statement

#000120677415002508 Filed on August 04, 2015

View on sec.gov

Income Statement

Concept 2015 Q3 2015 Q2 2014 Q2
Revenue $445.8K $803.5K $395.6K
YoY Change -1.57% 103.1% -24.19%
Cost Of Revenue $900.0K $960.0K $1.200M
YoY Change 15.38% -20.0% 23.71%
Gross Profit -$450.0K -$160.0K -$800.0K
YoY Change 36.36% -80.0% 77.78%
Gross Profit Margin -100.93% -19.91% -202.21%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development $327.4K $334.5K $349.6K
YoY Change 0.97% -4.32% -11.33%
% of Gross Profit
Depreciation & Amortization $50.00K $30.00K $0.00
YoY Change 400.0% -100.0%
% of Gross Profit
Operating Expenses $1.223M $1.296M $1.546M
YoY Change 10.9% -16.16% 17.8%
Operating Profit -$766.7K -$492.8K -$1.150M
YoY Change 18.06% -57.17% 39.12%
Interest Expense $10.00K $10.00K $10.00K
YoY Change 0.0% 0.0% 0.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$770.0K -$480.0K -$1.140M
YoY Change 20.31% -57.89% 46.25%
Income Tax
% Of Pretax Income
Net Earnings -$757.3K -$481.3K -$1.142M
YoY Change 18.37% -57.85% 39.97%
Net Earnings / Revenue -169.86% -59.9% -288.63%
Basic Earnings Per Share
Diluted Earnings Per Share -$32.08K -$19.99K -$48.41K
COMMON SHARES
Basic Shares Outstanding 24.03M shares 23.12M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q3 2015 Q2 2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $7.940M $7.100M $12.57M
YoY Change -32.25% -43.52% 3.97%
Cash & Equivalents $6.428M $5.595M $7.493M
Short-Term Investments $1.510M $1.500M $5.080M
Other Short-Term Assets $80.00K $90.00K $50.00K
YoY Change 0.0% 80.0% -16.67%
Inventory
Prepaid Expenses
Receivables $1.770M $1.730M $1.042M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $9.780M $8.921M $13.67M
YoY Change -24.87% -34.73% 5.19%
LONG-TERM ASSETS
Property, Plant & Equipment $880.0K $927.1K $96.67K
YoY Change 481.32% 859.02% 32.57%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $1.510M
YoY Change
Other Assets $30.00K $33.57K $33.57K
YoY Change -10.62% 0.0% 67.84%
Total Long-Term Assets $920.0K $2.469M $130.2K
YoY Change 397.45% 1795.99% 36.34%
TOTAL ASSETS
Total Short-Term Assets $9.780M $8.921M $13.67M
Total Long-Term Assets $920.0K $2.469M $130.2K
Total Assets $10.70M $11.39M $13.80M
YoY Change -18.95% -17.45% 5.42%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $80.00K $100.4K $110.8K
YoY Change 12.03% -9.4% -0.42%
Accrued Expenses $270.0K $265.7K $194.4K
YoY Change 45.01% 36.68% 49.53%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $360.0K $388.8K $327.7K
YoY Change 31.46% 18.65% -10.79%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $360.0K $388.8K $327.7K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $360.0K $390.0K $330.0K
YoY Change 33.33% 18.18% -10.81%
SHAREHOLDERS EQUITY
Retained Earnings -$95.48M
YoY Change 6.28%
Common Stock $109.0M
YoY Change 6.23%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $10.34M $11.00M $13.47M
YoY Change
Total Liabilities & Shareholders Equity $10.70M $11.39M $13.80M
YoY Change -18.95% -17.45% 5.42%

Cashflow Statement

Concept 2015 Q3 2015 Q2 2014 Q2
OPERATING ACTIVITIES
Net Income -$757.3K -$481.3K -$1.142M
YoY Change 18.37% -57.85% 39.97%
Depreciation, Depletion And Amortization $50.00K $30.00K $0.00
YoY Change 400.0% -100.0%
Cash From Operating Activities -$710.0K -$1.040M -$1.100M
YoY Change -10.13% -5.45% 44.74%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$130.0K $0.00
YoY Change -100.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities $1.500M -$10.00K $0.00
YoY Change -150.0% -100.0%
Cash From Investing Activities $1.500M -$140.0K -$10.00K
YoY Change -149.02% 1300.0% -66.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $3.278M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 50.00K 240.0K 3.500M
YoY Change -93.14%
NET CHANGE
Cash From Operating Activities -710.0K -1.040M -1.100M
Cash From Investing Activities 1.500M -140.0K -10.00K
Cash From Financing Activities 50.00K 240.0K 3.500M
Net Change In Cash 840.0K -940.0K 2.390M
YoY Change -121.82% -139.33% -402.53%
FREE CASH FLOW
Cash From Operating Activities -$710.0K -$1.040M -$1.100M
Capital Expenditures $0.00 -$130.0K $0.00
Free Cash Flow -$710.0K -$910.0K -$1.100M
YoY Change -1.39% -17.27% 50.68%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
490623 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
490623 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
44520 USD
us-gaap Payments To Acquire Held To Maturity Securities
PaymentsToAcquireHeldToMaturitySecurities
2545 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-47065 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1627249 USD
CY2015Q2 us-gaap Assets Current
AssetsCurrent
8920647 USD
CY2015Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
100390 USD
CY2015Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5594919 USD
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
110210480 USD
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7569537 USD
CY2015Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
305171 USD
CY2014Q4 us-gaap Long Term Investments
LongTermInvestments
1503525 USD
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2015Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
94656 USD
CY2015Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
927056 USD
CY2015Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
33567 USD
CY2015Q2 us-gaap Assets
Assets
11389874 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
17236 USD
us-gaap Net Income Loss
NetIncomeLoss
-2311843 USD
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.10
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23337166 shares
us-gaap Revenues
Revenues
703967 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2233606 USD
CY2015Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
265704 USD
CY2015Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
22722 USD
CY2015Q2 us-gaap Liabilities Current
LiabilitiesCurrent
388816 USD
us-gaap Operating Expenses
OperatingExpenses
3033046 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-2329079 USD
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7493372 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
12218 USD
us-gaap Share Based Compensation
ShareBasedCompensation
329067 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
175015 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-71476 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-2500 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
167873 USD
CY2015Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2015Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2015Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24030846 shares
CY2015Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
1503790 USD
CY2015Q2 us-gaap Long Term Investments
LongTermInvestments
1508604 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-1908724 USD
CY2014Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
305171 USD
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2015Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
961727 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
304788 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
3583038 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2147130 USD
us-gaap Basis Of Accounting
BasisOfAccounting
<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <p align="justify"><font style="text-decoration: underline;"><font style="font-size: 10pt;">Basis of Presentation</font></font><font style="font-size: 10pt;"></font></p> <p align="justify"><font style="font-size: 10pt;">The accompanying unaudited consolidated condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#147;GAAP&#148;) for interim financial information and with the instructions to Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. All such adjustments are of a normal recurring nature. Operating results for the three and six months ended June 30, 2015 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2015. For further information, refer to the consolidated financial statements and footnotes thereto included in the Annual Report on Form 10-K relating to Research Frontiers Incorporated (the &#147;Company&#148;) for the fiscal year ended December 31, 2014.</font></p> </div>
us-gaap Share Based Goods And Nonemployee Services Transaction Valuation Method Risk Free Interest Rate
ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate
0.017 pure
us-gaap Share Based Goods And Nonemployee Services Transaction Valuation Method Risk Free Interest Rate
ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate
0.017 pure
us-gaap Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Term1
ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1
P8Y10M24D
us-gaap Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Term1
ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1
P5Y6M
us-gaap Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Volatility Rate
ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate
0.65 pure
us-gaap Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Volatility Rate
ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate
0.58 pure
us-gaap Nature Of Operations
NatureOfOperations
<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <p align="justify"><font style="text-decoration: underline;"><font style="font-size: 10pt;">Business</font></font><font style="font-size: 10pt;"></font></p> <p align="justify" style="color: #000000; font-family: 'Times New Roman'; font-size: medium; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px;"><font size="2">Research Frontiers Incorporated (&#147;Research Frontiers&#148; or the &#147;Company&#148;) operates in a single business segment which is engaged in the development and marketing of technology and devices to control the flow of light. Such devices, often referred to as &#147;light valves&#148; or suspended particle devices (SPDs), use colloidal particles that are either incorporated within a liquid suspension or a film, which is usually enclosed between two sheets of glass or plastic having transparent, electrically conductive coatings on the facing surfaces thereof. At least one of the two sheets is transparent. SPD technology, made possible by a flexible light-control film invented by Research Frontiers, allows the user to instantly and precisely control the shading of glass/plastic manually or automatically. SPD technology has numerous product applications, including: SPD-Smart&#153; windows, sunshades, skylights and interior partitions for homes and buildings; automotive windows; sunroofs, sun-visors, sunshades, rear-view mirrors, instrument panels and navigation systems; aircraft windows; eyewear products; frames, cases and partitions protecting light-sensitive artwork, documents and artifacts; and flat panel displays for electronic products. SPD-Smart light control film is now being developed for, or used in, architectural, automotive, marine, aerospace and appliance applications.</font></p> <p align="justify" style="color: #000000; font-family: 'Times New Roman'; font-size: medium; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px;"><font size="2">The Company has historically utilized its cash and the proceeds from the sale of its investments to fund its research and development of SPD light valves, for marketing initiatives, and for other working capital purposes. The Company's working capital and capital requirements depend upon numerous factors, including the results of research and development activities, competitive and technological developments, the timing and cost of patent filings, and the development of new licensees and changes in the Company's relationships with its existing licensees. The degree of dependence of the Company's working capital requirements on each of the forgoing factors cannot be quantified; increased research and development activities and related costs would increase such requirements; the addition of new licensees may provide additional working capital or working capital requirements, and changes in relationships with existing licensees would have a favorable or negative impact depending on the nature of such changes. There can be no assurance that expenditures will not exceed the anticipated amounts or that additional financing, if required, will be available when needed or, if available, that's its terms will be favorable or acceptable to the Company. Eventual success of the Company and generation of positive cash flow will be dependent upon the commercialization of products using the Company's technology by the Company's licensees and payments of continuing royalties on account thereof. To date, the Company has not generated sufficient revenue from its licensees to fully fund its operations.</font></p> </div>
dei Document Type
DocumentType
10-Q
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2015Q2 us-gaap Revenues
Revenues
803494 USD
CY2014Q2 us-gaap Revenues
Revenues
395619 USD
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
CY2014Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1196445 USD
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
334518 USD
CY2014Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
349627 USD
CY2015Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
8600000 USD
dei Entity Registrant Name
EntityRegistrantName
RESEARCH FRONTIERS INC
CY2015Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
24030846 shares
dei Document Period End Date
DocumentPeriodEndDate
2015-06-30
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0000793524
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2015Q2 us-gaap Operating Expenses
OperatingExpenses
1296245 USD
CY2014Q2 us-gaap Operating Expenses
OperatingExpenses
1546072 USD
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-492751 USD
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1150453 USD
CY2015Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
11464 USD
CY2014Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
8595 USD
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-481287 USD
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-1141858 USD
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2014Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.05
CY2015Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
24005909 shares
CY2014Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23554685 shares
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3278250 USD
CY2014Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
750000 shares
CY2014Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3278250 USD

Files In Submission

Name View Source Status
0001206774-15-002508-index-headers.html Edgar Link pending
0001206774-15-002508-index.html Edgar Link pending
0001206774-15-002508.txt Edgar Link pending
0001206774-15-002508-xbrl.zip Edgar Link pending
exhibit31-1.htm Edgar Link pending
exhibit31-2.htm Edgar Link pending
exhibit32-1.htm Edgar Link pending
exhibit32-2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
refr-20150630.xml Edgar Link completed
refr-20150630.xsd Edgar Link pending
refr-20150630_cal.xml Edgar Link unprocessable
refr-20150630_def.xml Edgar Link unprocessable
refr-20150630_lab.xml Edgar Link unprocessable
refr-20150630_pre.xml Edgar Link unprocessable
refr_10q.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending